Back

Safety and efficacy of coronary sinus narrowing for treating refractory angina in real-world setting - single center experience

30 August 2026 (17:15 - 17:45)
Organised by: Logo
Congress Presentation Part of: Innovative therapeutic strategies in coronary artery disease Revascularisation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Ms Joanna Grygier

Poznan University of Medical Sciences, Poznan (Poland)

4 More presentations in this session

Presentation thumbnail
Spinal Cord Stimulation in patients with Refractory Angina Pectoris (SCRAP); double-blind, placebo-controlled, cross-over randomized controlled trial
Miss F. Vervaat (Eindhoven, NL)
Abstract
Presentation thumbnail
The effects of STAtin-FENOfibrate combination therapy vs. statin monotherapy on necrotic core and plaque characteristics in non-diabetic patients with combined dyslipidemia and intermediate CAOD
Professor S. Han (Incheon, KR)
Abstract
Presentation thumbnail
Long-term adherence to secondary preventive medications after myocardial infarction: a post-hoc analysis of the BETAMI trial
Ms A. Bakken (Oslo, NO)
Abstract
Presentation thumbnail
Natriuretic peptides reverse vascular insulin resistance and supress insulin-induced mechanisms of atherogenesis
Doctor D. Foran (Oxford, GB)
Abstract

Access the full session

Session thumbnail
Innovative therapeutic strategies in coronary artery disease

The Event

Event poster

ESC Congress 2026

30 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Coronary sinus reducer device for the treatment of refractory angina therapy. A multicentric initial experience.
26 August 2022
thumbnail
Congress Presentation
Real-world data from the use of ranolazine in patients with stable angina pectoris: the RANGER study
29 August 2022
thumbnail
Congress Presentation
Predictors for change in quality of life in patients with chronic coronary syndrome undergoing PCI
31 August 2025
thumbnail
Congress Presentation
Safety, tolerability and diagnostic ability of a novel 18F-labelled tracer, [18F]SYN2, for PET myocardial perfusion imaging (SAFER) in patients with suspected coronary artery disease - phase II trial
20 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources